Effect of Alicizumab on Blood Lipid and Inflammatory Response After PCI in Patients with ST Segment Elevation Myocardial Infarction
Objective To investigate the effect of alicizumab on blood lipid and inflammatory response after percutane-ous coronary intervention(PCI)in patients with ST-elevation myocardial infarction(STEMI).Methods A total of 120 STEMI patients who underwent PCI in Xianyou County General Hospital of Fujian Province from June 2022 to Febru-ary 2024 were randomly selected as the research objects.According to different treatment methods,they were divided into two groups,with 60 cases in each group.The control group was given routine lipid regulation after operation,and the observation group was treated with alicizumab on the basis of the control group.The blood lipid status,inflamma-tory response and safety of the two groups were compared.Results At 1 week and 3 months after PCI,the level of three blood lipid indexes(total cholesterol,low density lipoprotein cholesterol and triglyceride)in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).At 1 week and 3 months after PCI,the level of two inflammatory indexes(high-sensitivity C-reactive protein and interleu-kin-6)in the observation group were lower than those in the control group,and the differences were statistically sig-nificant(all P<0.05).The total incidence of drug-related adverse reactions in the observation group was 5.00%(3/60),which was similar to 8.33%(5/60)in the control group,and the difference was not statistically significant(χ2=0.133,P=0.714).Conclusion Alicizumab can quickly reduce blood lipid levels and inflammatory factor levels in STEMI pa-tients after PCI,and ensure drug safety.
NETL
NSTL
万方数据
